BHV-0223 Expanded Access Program Opened for ALS, as FDA Application Is Prepared
May 9th 2018An expanded access program has been opened to allow patients with ALS access to BHV-0223, a sublingual formulation of riluzole, all while Biohaven Pharmaceutical prepares a new drug application for the drug.